The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Intensive glucose control in patients with type 2 diabetes - 15-year follow-up.
Open accessAbstract
BACKGROUND: We previously reported that a median of 5.6 years of intensive as compared with standard glucose lowering in 1791 military veterans with type 2 diabetes resulted in a risk of major cardiovascular events that was significantly lower (by 17%) after a total of 10 years of combined intervention and observational follow-up. We now report the full 15-year follow-up. METHODS: We observationally followed enrolled participants (complete cohort) after the conclusion of the original clinical trial by using central databases to identify cardiovascular events, hospitalizations, and deaths. Participants were asked whether they would be willing to provide additional data by means of surveys and chart reviews (survey cohort). The prespecified primary outcome was a composite of major cardiovascular events, including nonfatal myocardial infarction, nonfatal stroke, new or worsening congestive heart failure, amputation for ischemic gangrene, and death from cardiovascular causes. Death from any cause was a prespecified secondary outcome. RESULTS: There were 1655 participants in the complete cohort and 1391 in the survey cohort. During the trial (which originally enrolled 1791 participants), the separation of the glycated hemoglobin curves between the intensive-therapy group (892 participants) and the standard-therapy group (899 participants) averaged 1.5 percentage points, and this difference declined to 0.2 to 0.3 percentage points by 3 years after the trial ended. Over a period of 15 years of follow-up (active treatment plus post-trial observation), the risks of major cardiovascular events or death were not lower in the intensive-therapy group than in the standard-therapy group (hazard ratio for primary outcome, 0.91; 95% confidence interval [CI], 0.78 to 1.06; P = 0.23; hazard ratio for death, 1.02; 95% CI, 0.88 to 1.18). The risk of major cardiovascular disease outcomes was reduced, however, during an extended interval of separation of the glycated hemoglobin curves (hazard ratio, 0.83; 95% CI, 0.70 to 0.99), but this benefit did not continue after equalization of the glycated hemoglobin levels (hazard ratio, 1.26; 95% CI, 0.90 to 1.75). CONCLUSIONS: Participants with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had a lower risk of cardiovascular events than those who received standard therapy only during the prolonged period in which the glycated hemoglobin curves were separated. There was no evidence of a legacy effect or a mortality benefit with intensive glucose control. (Funded by the VA Cooperative Studies Program; VADT ClinicalTrials.gov number, NCT00032487.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–225 of 225
“Here it was waiting for me:” Diabetes Diagnosis Pathways and Implications for Health Policy
Chard, S. E., Girling, L., Harris‐Wallace, B., Henderson, L., Roth, E. G., & Eckert, J. K. (2022) · Journal of Elder Policy · doi:10.18278/jep.2.2.4
Remission of Type 2 Diabetes with High-Fiber, Low-Fat, and Calorie Restricted Plant-Based Diet Study
Gunadhar, P. (2023) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410167
Mühlhauser, I., Buhse, S., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_34
Wang, I., Wang, T.-Y., Yu, T., Yen, T., Yip, H., Li, C., Lai, P., & Sung, F. (2023) · Research Square · doi:10.21203/rs.3.rs-3459864/v1
Intervención Educativa Sobre Insulinoterapia a Médicos de la Unidad de Medicina Familiar No 73
Iruegas, J. E. G., Melchor, M. E. V., & Hernández, M. (2023) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v7i5.8323
Shereshneva, M. V., & Ilyin, M. V. (2023) · Медицинская этика · doi:10.24075/medet.2023.033
Ischaemic Heart Disease in Diabetes
Lehrke, M., & Marx, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch49
Utilização de probióticos como adjuvantes na terapia convencional do Diabetes
Bock, P. M. (2024) · VITTALLE - Revista de Ciências da Saúde · doi:10.14295/vittalle.v36i1.16717
León, J. S. T., Ardila, L. J. P., Santamaria, M. J. C., Quintero, V. Q., Campo, E. R. Z., Corzo, M. J. O., Cantillo, F. A. A., Romero, L. D. J., Medina, R. A. A., Solano, M. J. C., et al. (2024) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v8i1.10179
Pallarés‐Carratalá, V., Ruiz‐García, A., Serrano-Cumplido, A., Segura‐Fragoso, A., Fernández-Pascual, V., Sánchez-Sánchez, B., Cervera-Pérez, M. I., Alonso-Moreno, F. J., Arranz-Martínez, E., Barquilla-García, A., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.arteri.2024.05.001
Do You Have Diabetes Mellitus?: How Diabetes and Its Treatments Are Linked to Kidney Disease
Rayner, H. C., Thomas, M. E., Dasgupta, I., Lalayiannis, A. D., & Hameed, M. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-66349-9_7
Detection and Treatment of Chronic Complications
Soe, K. K., & Gunasekaran, U. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch05
Ogawa, M., & Tanaka, Y. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009566
Tan, J., Lim, G. H., Tan, H. Y., Sng, G. G. R., Thumboo, J., & Mong, B. Y. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5236698
Optimizing polypharmacy in elderly with diabetes through routine benefit–risk assessment
AL‐Musawe, L., Ismael, A. H., & Al-Mukhtar, E. J. (2024) · Aging Research · doi:10.26599/agr.2025.9340038
Matsui, M., Nishimoto, M., Uemura, T., Kitamura, S., Tato, W., Tsushima, H., Kosugi, T., Eriguchi, M., Samejima, K., Mita, M., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04649-4
Sun, Y., Ni, W., Yuan, X., 池洪珊, & Xu, J. (2020) · Figshare · doi:10.6084/m9.figshare.12569675
Tye, S. C., Jongs, N., Coca, S. G., Sundström, J., Arnott, C., Neal, B., Perkovic, V., Mahaffey, K. W., Vart, P., & Heerspink, H. J. L. (2022) · Figshare · doi:10.6084/m9.figshare.21200741
A Natural Sweetener‐inducible Genetic Switch Controls Therapeutic Protein Expression in Mammals
Qiao, L., Wang, Z., Tang, S., Fang, Y., Yu, G., Qiu, X., Niu, L., Yan, T., Liu, X., Ma, X., et al. (2026) · Advanced Science · doi:10.1002/advs.202514226
Asiamah-Asare, B. K. Y., Randall, S. M., Mnatzaganian, G., Varhol, R., Lee, C., Chai, K. E. K., Boyd, J., Shakya, S., Gao, L., Robinson, S., et al. (2026) · Value in Health Regional Issues · doi:10.1016/j.vhri.2026.101615
Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors
Elezaby, A., Nayor, M. G., & Alexander, K. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00096-0
Les traitements du diabète de type 2 : les preuves
Bordier, L., & Bauduceau, B. (2026) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2026.100822
James, F., Li, Q., Somisetty, M., Nguyen, C., Vaughan‐Sarrazin, M., Lund, B. C., Tsai, S. X., Smolderen, K. G. E., Hoffman, R. M., Arya, S., et al. (2026) · medRxiv · doi:10.64898/2026.06.18.26356017
Bruggeman, B. S., Jacobsen, L. M., Foster, T. P., & Winter, W. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-21725-8.00005-6
Metadata
- Authors
- Reaven, P. D., Emanuele, N. V., Wiitala, W. L., Bahn, G. D., Reda, D. J., McCarren, M., Duckworth, W. C., & Hayward, R. A.
- Affiliations
- VA Ann Arbor Healthcare System (US)
- Edward Hines, Jr. VA Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-06
- Volume
- 380
- Issue
- 23
- Pages
- 2215-2224
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6706253
- OpenAlex
- W2955148946
- Cited by
- 228
- References
- 36
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 21 · 2023: 35 · 2022: 35 · 2021: 34 · 2020: 50 · 2019: 27
- FWCI
- 29.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- VA Cooperative Studies Program (NCT00032487)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tight glycemic control, type 2 diabetes, HbA1c, cardiovascular events, major adverse cardiovascular events, long-term follow-up, military veterans, glycemic control, cardiovascular mortality, myocardial infarction, stroke, congestive heart failure, amputation
- MeSH terms
- Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Middle Aged, Quality of Life, Veterans, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
